Dagmar Kubitza
Bayer (Germany)(DE)
Publications by Year
Research Areas
Venous Thromboembolism Diagnosis and Management, Atrial Fibrillation Management and Outcomes, Blood Coagulation and Thrombosis Mechanisms, Antibiotics Pharmacokinetics and Efficacy, Cardiac Arrhythmias and Treatments
Most-Cited Works
- → Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor(2005)652 cited
- → Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—after multiple dosing in healthy male subjects(2005)648 cited
- → Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban(2013)590 cited
- → Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor(2010)428 cited
- → Metabolism and Excretion of Rivaroxaban, an Oral, Direct Factor Xa Inhibitor, in Rats, Dogs, and Humans(2009)374 cited
- → Co‐administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects(2013)364 cited
- → Body Weight Has Limited Influence on the Safety, Tolerability, Pharmacokinetics, or Pharmacodynamics of Rivaroxaban (BAY 59‐7939) in Healthy Subjects(2007)330 cited
- → Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial(2019)299 cited
- → Pharmacokinetics, Safety, and Tolerability of Ascending Single Doses of Moxifloxacin, a New 8-Methoxy Quinolone, Administered to Healthy Subjects(1998)296 cited
- → The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor(2010)291 cited